Cholecystokinin Receptor

CCK Receptor

Cholecystokinin receptors are a group of G-protein coupled receptors which bind the peptide hormones cholecystokinin (CCK) and gastrin. Two types of functional membrane receptors, cholecystokinin A receptor (CCK-AR), located mainly on pancreatic acinar cells, and CCK-BR, mostly in the stomach and nervous system tissues, have been identified as the endogenous receptors of CCK. Both have high affinity for the sulfated CCK octapeptide (CCK-8), whereas only the CCK-BR has high affinity for gastrin.</P>

CCK is a peptide hormone discovered in the small intestine. Together with secretin and gastrin, CCK constitutes the classical gut hormone triad. In addition to gallbladder contraction, CCK also regulates pancreatic enzyme secretion and growth, intestinal motility, satiety signalling and the inhibition of gastric acid secretion. CCK is also a transmitter in central and intestinal neurons.

(Rac)-Sograzepide

((Rac)-Netazepide; (Rac)-YF 476; (Rac)-YM-220)

Cat. No.: HY-U00360



(Rac)-Sograzepide is an antagonist of cholecystokinin B **(CCK-B) receptor**, and has the potential of reducing the secretion of gastric acid.

Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

A71623

Cat. No.: HY-P1096



A71623, a CCK-4-based peptide, is a potent and highly selective **CCK-A** full agonist. The IC_{50}s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CCK-A receptor inhibitor 1

Cat. No.: HY-U00387



CCK-A receptor inhibitor 1 is a **cholecystokinin A (CCK-A) receptor** inhibitor with a binging IC_{50} of 340 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCK-B Receptor Antagonist 2

Cat. No.: HY-129357



CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active **Gastrin/CCK-B** antagonist with an IC_{50} value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC_{50} of 1.82 μM.

Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ceruletide

(Caerulein; Cerulein; FI-6934)

Cat. No.: HY-A0190



Ceruletide is a decapeptide and a potent **cholecystokinin receptor** agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.

Purity: 99.96%
Clinical Data: Launched
Size: 100 μg, 500 μg x 2, 500 μg

CHEMBL333994

(FK-480)

Cat. No.: HY-U00363



CHEMBL333994 is a potent and orally effective Cholecystokinin A **(CCK-A)** antagonist, with an IC_{50} of 0.67 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CI-988

(PD134308)

Cat. No.: HY-105226



CI-988 (PD134308) is a potent, selective and orally active **CCK2R (cholecystokinin 2 receptor)** antagonist with an IC_{50} of 1.7 nM for mouse cortex CCK2. CI-988 shows >1600-fold selectivity for CCK2 over CCK1 receptor. CI-988 has anxiolytic and anti-tumor effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Devazepide

(L-364,718; MK-329)

Cat. No.: HY-106301



Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of **cholecystokinin (CCK) receptor**, with IC_{50}s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively.

Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dexloxiglumide

Cat. No.: HY-128878



Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8).

Purity: 98.25%
Clinical Data:
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Gastrazole

(JB95008)

Cat. No.: HY-19445



Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gastrin I, human

Cat. No.: HY-P1097

Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via **cholecystokinin 2 (CCK2)** receptor.

pE-GPWLEEEEEAYGWMDF-NH_2

Purity: 99.93%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gastrin I, rat

(Rat Gastrin-17)

Cat. No.: HY-P2416

Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently.

Pyr-RPPMEEEEEAYGWMDF-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gastrin/CCK antagonist 1

Cat. No.: HY-U00375

Gastrin/CCK antagonist 1 is an antagonist of **gastrin/CCK**, used for the research of gastrointestinal disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GI 181771

Cat. No.: HY-11076

GI 181771 is a **cholecystokinin 1** receptor agonist investigated for the treatment of obesity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-365260

Cat. No.: HY-106840

L-365260 is a potent and selective antagonist of non-peptide **gastrin** and **brain cholecystokinin receptor (CCK-B)**, with K_is of 1.9 nM and 2.0 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lintitript

(SR 27897)

Cat. No.: HY-101764

Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide **cholecystokinin (CCK1) receptor** antagonist with an EC_{50} of 6 nM and a K_i of 0.2 nM.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Lorglumide sodium salt

(CR-1409 sodium salt)

Cat. No.: HY-B1439B

Lorglumide sodium salt (CR-1409 sodium salt) is a potent **cholecystokinin** (**CCK**) **receptor** antagonist.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Loxiglumide

(CR-1505)

Cat. No.: HY-B2154

Loxiglumide is a cholecystokinin (**CCK-1**) receptor antagonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

LY288513

Cat. No.: HY-103357

LY288513 is a selective non-peptide **CCK-B** receptor antagonist with an IC_{50} value of 16 nM. LY288513 produces an anxiolytic-like action in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mini Gastrin I, human

Cat. No.: HY-P1593

Mini Gastrin I, human is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

LEEEEEAYGWMDF-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mini Gastrin I, human TFA

Cat. No.: HY-P1593A

Mini Gastrin I, human (TFA) is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

LEEEEEAYGWMDF-NH_2 (TFA salt)

Purity: 98.08%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nastorazepide

(Z-360)

Cat. No.: HY-17617

Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pentagastrin

(ICI-50123)

Cat. No.: HY-A0261

Pentagastrin (ICI-50123) is a selective agonist of **Cholecystokinin B (CCK_B) receptor** with an **IC_{50}** of 11 nM. Pentagastrin enhances gastric mucosal defence mechanisms against acid and protects the gastric mucosa from experimental injury.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Proglumide

Cat. No.: HY-B1330

Proglumide is a nonpeptide and orally active **cholecystokinin (CCK)-A/B receptors** antagonist. Proglumide selective blocks **CCK**'s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Proglumide hemicalcium

Cat. No.: HY-103354A

Proglumide hemicalcium is a nonpeptide and orally active **cholecystokinin (CCK)-A/B receptors** antagonist. Proglumide hemicalcium selective blocks **CCK**'s effects in the central nervous system (CNS).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Proglumide sodium

Cat. No.: HY-103354

Proglumide sodium is a nonpeptide and orally active **cholecystokinin (CCK)-A/B receptors** antagonist. Proglumide sodium selective blocks **CCK**'s effects in the central nervous system (CNS).



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Sograzepide

(Netazepide; YF 476; YM-220)

Cat. No.: HY-14850

Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent , highly selective and orally active **Gastrin/CCK-B** antagonist with an **IC_{50}** value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an **IC_{50}** of 502...



Purity: 98.51%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sograzepide-d3

(Netazepide-d3; YF 476-d3; YM-220-d3)

Cat. No.: HY-14850S

Sograzepide-d3 (Netazepide-d3) is the deuterium labeled Sograzepide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR 146131

Cat. No.: HY-11077

SR 146131 is a potent, orally available, and selective nonpeptide (**cholecystokinin 1**) receptor agonist.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Tarazepide

Cat. No.: HY-U00062

Tarazepide is a potent and specific **CCK-A** receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetragastrin

(Cholecystokinin tetrapeptide; CCK-4) **Cat. No.:** HY-125556

Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion. Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist. Gastric mucosal protection.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg